Literature DB >> 12552020

Characterization of tissue tropism determinants of adeno-associated virus type 1.

Bernd Hauck1, Weidong Xiao.   

Abstract

Muscle is an attractive target for gene delivery because of its mass and because vectors can be delivered in a noninvasive fashion. Adeno-associated virus (AAV) has been shown to be effective for muscle-targeted gene transfer. Recent progress in characterization of AAV serotype 1 (AAV1) and AAV6 demonstrated that these two AAV serotypes are far more efficient in transducing muscle than is the traditionally used AAV2. Since all cis elements are identical in these vectors, the potential determinants for their differences in transducing muscle appear to be located within the AAV capsid proteins. In the present study, a series of AAV capsid mutants were generated to identify the major regions affecting AAV transduction efficiency in muscle. Replacement of amino acids 350 to 736 of AAV2 VP1 with the corresponding amino acids from VP1 of AAV1 resulted in a hybrid vector that behaved very similarly to AAV1 in vitro and in vivo in muscle. Characterization of additional mutants carrying smaller regions of the AAV1 VP1 amino acid sequence in the AAV2 capsid protein suggested that amino acids 350 to 430 of VP1 function as a major tissue tropism determinant. Further analysis showed that the heparin binding domain and the major antigenic determinants in the AAV capsid region were not necessary for the efficiency of AAV1 transduction of muscle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552020      PMCID: PMC141099          DOI: 10.1128/jvi.77.4.2768-2774.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

Authors: 
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.

Authors:  H Chao; Y Liu; J Rabinowitz; C Li; R J Samulski; C E Walsh
Journal:  Mol Ther       Date:  2000-12       Impact factor: 11.454

3.  Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells.

Authors:  D M Kube; S Ponnazhagan; A Srivastava
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

5.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3.

Authors:  S Muramatsu; H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

7.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.

Authors:  C Summerford; J S Bartlett; R J Samulski
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

9.  Cloning and characterization of adeno-associated virus type 5.

Authors:  J A Chiorini; F Kim; L Yang; R M Kotin
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface.

Authors:  J P Langeveld; J I Casal; C Vela; K Dalsgaard; S H Smale; W C Puijk; R H Meloen
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  40 in total

1.  Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.

Authors:  Joseph E Rabinowitz; Dawn E Bowles; Susan M Faust; Julie G Ledford; Scott E Cunningham; R Jude Samulski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

3.  Transient demyelination increases the efficiency of retrograde AAV transduction.

Authors:  Edmund R Hollis; Pouya Jamshidi; Ariana O Lorenzana; Jae K Lee; Steven J Gray; Richard J Samulski; Binhai Zheng; Mark H Tuszynski
Journal:  Mol Ther       Date:  2010-05-25       Impact factor: 11.454

4.  Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors.

Authors:  Sifeng Chen; Matthias Kapturczak; Scott A Loiler; Sergei Zolotukhin; Olena Y Glushakova; Kirsten M Madsen; Richard J Samulski; William W Hauswirth; Martha Campbell-Thompson; Kenneth I Berns; Terence R Flotte; Mark A Atkinson; C Craig Tisher; Anupam Agarwal
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

5.  Microvesicle-associated AAV vector as a novel gene delivery system.

Authors:  Casey A Maguire; Leonora Balaj; Sarada Sivaraman; Matheus H W Crommentuijn; Maria Ericsson; Lucia Mincheva-Nilsson; Vladimir Baranov; Davide Gianni; Bakhos A Tannous; Miguel Sena-Esteves; Xandra O Breakefield; Johan Skog
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

6.  Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Authors:  Michael A Lochrie; Gwen P Tatsuno; Brian Christie; Jennifer Wellman McDonnell; Shangzhen Zhou; Richard Surosky; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 7.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

Review 8.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 9.  State-of-the-art gene-based therapies: the road ahead.

Authors:  Mark A Kay
Journal:  Nat Rev Genet       Date:  2011-04-06       Impact factor: 53.242

10.  Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals.

Authors:  A Asokan; J S Johnson; C Li; R J Samulski
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.